The miseducation of algorithms is a critical problem; when artificial intelligence mirrors unconscious thoughts, racism, and biases of the humans who generated these algorithms, it can lead to serious harm. Computer programs, for example, have wrongly flagged Black defendants as twice as likely to reoffend as someone who's white. When an AI used cost as a proxy for health needs, it falsely named Black patients as healthier than equally sick white ones, as less money was spent on them. Even AI used to write a play relied on using harmful stereotypes for casting. Removing sensitive features from the data seems like a viable tweak.
We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. There are almost 350 million people worldwide with blindness or some other form of visual impairment who need to use the internet and mobile apps just like anyone else. Yet, they can only do so if websites and mobile apps are built with accessibility in mind -- and not as an afterthought. Consider these two sample buttons that you might find on a web page or mobile app. Each has a simple background, so they seem similar.
In the past five years, interest in applying artificial intelligence (AI) approaches in drug research and development (R&D) has surged. Driven by the expectation of accelerated timelines, reduced costs and the potential to reveal hidden insights from vast datasets, more than 150 companies with a focus on AI have raised funding in this period, based on an analysis of the field by Back Bay Life Science Advisors (Figure 1a). And the number of financings and average amount raised soared in 2021. At the forefront of this field are companies harnessing AI approaches such as machine learning (ML) in small-molecule drug discovery, which account for the majority of financings backed by venture capital (VC) in recent years (Figure 1b), as well as some initial public offerings (IPOs) for pioneers in the area (Table 1). Such companies have also attracted large pharma companies to establish multiple high-value partnerships (Table 2), and the first AI-based small-molecule drug candidates are now in clinical trials (Nat.
Patterns of speech in a phone conservation can be used to correctly identify adults in the early stages of Alzheimer's disease, a study published Wednesday by the journal PLOS found. Using more than 1,600 voice recordings of phone conversations made from 24 people with confirmed Alzheimer's and 99 healthy controls, researchers correctly identified those with the common form of dementia with roughly 90% accuracy, the data showed. The approach relies on the tendency of people with Alzheimer's "to speak more slowly and with longer pauses and to spend more time finding the correct word," the researchers said. These "vocal features" result in "broken messages and lack of speech fluency," which can be analyzed using an artificial intelligence-based program. The computer program was able to identify those with early Alzheimer's with essentially the same level of accuracy as a telephone-based test for cognitive function, according to the researchers.
Combinostics, a neurology technology company looking at everything from early detection and diagnosis to the ongoing management of neurological disorders, has announced the Dementia Differential Analysis report, which aims to assist clinicians in the detection and differential diagnosis of dementias. The report will be available in an upcoming software release. Existing technologies compare against cognitively normal reference data only – the artificial intelligence-enabled application quantifies and evaluates patient MRI data against the distributions of key dementia-specific imaging biomarkers and reference data from approximately 2,000 patients with a confirmed neurodegenerative disease, including frontotemporal dementia, Alzheimer's disease and vascular dementia, the company explained. "The Dementia Differential Analysis report will help change the paradigm of diagnosing dementias," contended Richard Hausmann, CEO of Combinostics. Using the company's AI technology, it enables differential diagnostic support, furthering the company's commitment to provide clinicians with tools for reliable, evidence-based diagnostic decisions, he added.
Eating a small bowl of cranberries every day could help ward off dementia, research suggested today. Scientists tested giving healthy older adults the equivalent of 100g of the fruit each day. Volunteers who ate a powdered version of the fruit -- which has a notoriously bitter taste -- were found to have a better memory recall after 12 weeks. And MRI scans showed those eating cranberries had better blood flow to important parts of the brain. People given cranberries also had 9 per cent lower bad cholesterol levels, according to the University of East Anglia study.
Left: The display that carers will see in the Milbotix app. Inventor Dr Zeke Steer quit his job and took a PhD at Bristol Robotics Laboratory so he could find a way to help people like his great-grandmother, who became anxious and aggressive because of her dementia. Milbotix's smart socks track heart rate, sweat levels and motion to give insights on the wearer's wellbeing – most importantly how anxious the person is feeling. They look and feel like normal socks, do not need charging, are machine washable and provide a steady stream of data to carers, who can easily see their patient's metrics on an app. Current alternatives to Milbotix's product are worn on wrist straps, which can stigmatise or even cause more stress.
It is predicted that technologies such as artificial intelligence (AI), cloud computing, extended reality and the Internet of Things (IoT) will be introduced further among related workers, leading to the development and provision of new and better treatments and services. In the months following the outbreak of the COVID-19 outbreak, the proportion of telemedicine consulting has risen sharply from 0.1% to 43.5%, and is expected to rise further in the future, as this trend could save more patients' lives, said Deloitte Accounting Firm analyst. . To achieve this goal, the next-generation portable device, heart rate, stress, and blood oximetry, enables doctors to accurately determine the patient's condition in real time. During the COVID-19 period, doctors built'virtual hospital rooms' in some areas to observe the treatment status of patients in various areas through the central communication infrastructure. The Pennsylvania Emergency Medical Center is developing a high-quality'virtual emergency room'.
Purpose: A reliable tool for outcome prognostication in severe traumatic brain injury (TBI) would improve intensive care unit (ICU) decision-making process by providing objective information to caregivers and family. This study aimed at designing a new classification score based on magnetic resonance (MR) diffusion metrics measured in the deep white matter between day 7 and day 35 after TBI to predict 1-year clinical outcome. Methods: Two multicenter cohorts (29 centers) were used. MRI-COMA cohort (NCT00577954) was split into MRI-COMA-Train (50 patients enrolled between 2006 and mid-2014) and MRI-COMA-Test (140 patients followed up in clinical routine from 2014) sub-cohorts. These latter patients were pooled with 56 ICU patients (enrolled from 2014 to 2020) from CENTER-TBI cohort (NCT02210221).